: The latest version of the dbPTM database (2025 update) has integrated over 2.7 million post-translational modification sites, providing a massive resource for scientists tracking how proteins like those from the ADAM family are modified after production. Future Directions in Treatment
The keyword "" is a highly specific search term primarily associated with genetic research and clinical updates regarding the ADAM33 gene (A Disintegrin and Metalloproteinase 33). This gene is widely recognized as a critical susceptibility factor for respiratory conditions, specifically asthma and bronchial hyperresponsiveness. The Biological Blueprint of ADAM33 adn333 upd
: Various Single Nucleotide Polymorphisms (SNPs) in this gene have been studied across diverse populations, including recent associations found in the Punjabi population of Pakistan. Recent Research & Clinical Updates (UPD) : The latest version of the dbPTM database
: It is believed to influence the structural changes in the lungs—a process called airway remodeling —which can lead to the permanent thickening of airway walls. The Biological Blueprint of ADAM33 : Various Single
While there is currently no direct "gene cure" for asthma, research into ADAM33 provides a foundation for . By targeting the structural cells of the lung rather than just the immune system, future therapies may be able to prevent the long-term damage caused by chronic respiratory disease.
: New studies using Olink targeted proteomics and machine learning are helping identify robust biomarker signatures for respiratory and inflammatory diseases.
ADAM33 is located on , a genomic region long linked to airway remodeling. Unlike many genes that focus on immune responses, ADAM33 is primarily expressed in mesenchymal cells , such as lung fibroblasts and smooth muscle cells.